A Study of Rusfertide in Japanese Adults With Polycythemia Vera
A phase 2 trial of Rusfertide in myeloproliferative neoplasms, run by Takeda, now recruiting.
Overview
A Study of Rusfertide in Japanese Adults With Polycythemia Vera is a phase 2 interventional study registered as NCT07648030 by Takeda, with 9 participants planned, started 2026-07-14 and due to reach its primary completion in 2027-10-28. Interventions recorded: Rusfertide.
Similar pages
not linked directly; found by shared links- TrialA Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
Shares Rusfertide, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Shares Rusfertide, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-505 in Adults With Solid Tumors
Shares Takeda and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Takeda and the tag pipeline.
- TrialStudy to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.